Title : Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.

Pub. Date : 2018 Mar

PMID : 29368050






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RESULTS: The administration of posaconazole 400 mg BID x 7 days with idasanutlin 800 mg resulted in a slight decrease (7%) in Cmax and a modest increase (31%) in AUC for idasanutlin, a marked reduction in Cmax (~ 60%) and AUC0 (~ 50%) for M4 metabolite, and a minimal increase (~ 24%) in serum MIC-1 levels. RG7388 growth differentiation factor 15 Homo sapiens